Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis

Next Previous
Trial Profile

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crisaborole (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms CrisADe CORE 1
  • Sponsors Anacor Pharmaceuticals; Pfizer

Most Recent Events

  • 01 Jan 2024 Results of post hoc pooled analysis from NCT02118766 and NCT02118792, assess the efficacy and safety of crisaborole in patients with AD who had received prior treatment with (a) corticosteroids (systemic or topical) or topical calcineurin inhibitors (TCIs) or (b) topical corticosteroids (TCSs) or TCIs or (c) who were treatment-naive , published in the Dermatitis
  • 22 Feb 2023 Results of an analysis impact of crisaborole on sleep outcomes in pediatric patients atopic dermatitis from three clinical studies: CORE-1, CORE-2 and CrisADe CARE 1 study published in the Dermatology and Therapy
  • 16 Mar 2022 Results of post-hoc pooled analysis of two studies (AD-301: NCT02118766; AD-302: NCT02118792) assessing efficacy and safety of crisaborole ointment for the treatment of mild-to-moderate atopic dermatitis in pediatric patients, published in the Pediatric Drugs.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top